DOVER, Del., Jan. 29, 2024 /PRNewswire/ -- Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target escape mutations in hematologic and solid malignancies, today announced the clearance from the Human Research Ethics Committee in Australia to begin human dosing in the Phase 1 clinical program of eiletoclax, a highly potent and selective BCL2 inhibitor..

多佛，Del。，2024年1月29日/PRNewswire/--Eilean Therapeutics LLC，一家生物制药公司，致力于发现和开发一流的小分子抑制剂，以靶向血液和实体恶性肿瘤的逃逸突变，今天宣布，澳大利亚人类研究伦理委员会批准在高效选择性BCL2抑制剂eiletoclax的第一阶段临床计划中开始人体给药。。

'The first in human dosing of eiletoclax in Australia represents another important milestone for Eilean Therapeutics, as we progress, with an accelerated development of our portfolio of best-in-class agents targeting hematological malignancies,' stated Iain Dukes, Chief Executive Officer of Eilean Therapeutics.

艾琳治疗公司首席执行官伊恩·杜克斯（IainDukes）表示：“随着我们的进步，澳大利亚首次在人体内服用艾琳治疗剂代表了艾琳治疗的另一个重要里程碑，我们加速了针对血液系统恶性肿瘤的一流药物组合的发展。”。

'The highly differentiated pre-clinical profile of eiletoclax emphasizes important advantages over venetoclax-like molecules in safety, tolerability and feasibility of outpatient treatment, enabling the molecule to safely target AML and CLL patients alone and in combination with other targeted therapies.'.

“eiletoclax的高度分化的临床前特征强调了在门诊治疗的安全性，耐受性和可行性方面优于venetoclax样分子的重要优势，使该分子能够单独安全靶向AML和CLL患者，并与其他靶向治疗相结合。”。

About Eiletoclax

关于Eiletoclax

Eiletoclax (ZE50-0134) has earlier reported best-in-class potency and selectivity against BCL2, a key pro-survival protein that is overexpressed in many cancers. This clinical candidate demonstrated equivalent in vivo anti-tumor efficacy as venetoclax in B cell and myeloid malignancy cell lines and in vivo models.

Eiletoclax（ZE50-0134）早些时候报道了对BCL2的最佳效力和选择性，BCL2是一种在许多癌症中过表达的关键促生存蛋白。该临床候选物在B细胞和骨髓恶性肿瘤细胞系和体内模型中表现出与venetoclax相当的体内抗肿瘤功效。

Compared to venetoclax, eiletoclax exhibits significantly less suppression of non-malignant immune cell populations, a result that suggests superior selectivity and an improved safety profile..

与venetoclax相比，eiletoclax对非恶性免疫细胞群的抑制作用明显减少，这表明其具有优异的选择性和改进的安全性。。

About Eilean Therapeutics

关于Eilean Therapeutics

Eilean Therapeutics LLC is a biopharmaceutical company co-founded by Orbimed, Torrey Pines Investment and Dr John C. Byrd, focused on the discovery and development of best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic and solid cancers. The company is utilizing a proprietary hybrid AI platform (Expert Systems Inc.), leveraging its key partners proprietary data, chem-bio platforms, knowledge and expertise to choose highly valuable molecular mechanisms of pathology; to precisely design and accelerate the execution of discovery and development of best-in-class and first-in-class therapies.

Eilean Therapeutics LLC是由Orbimed，Torrey Pines Investment和John C.Byrd博士共同创立的生物制药公司，专注于发现和开发针对血液和实体癌逃逸突变的一流和一流小分子抑制剂。该公司正在利用专有的混合人工智能平台（Expert Systems Inc.），利用其关键合作伙伴专有数据，化学生物平台，知识和专业知识来选择极具价值的病理分子机制；精确设计并加速发现和开发一流和一流疗法的执行。

Eilean Therapeutics' goal is to utilize its capabilities and platform to become a leader in developing novel breakthrough medicines to maximize the clinical benefit when treating hematologic and solid malignancies. For more information visit www.eileanther.com.

Eilean Therapeutics的目标是利用其能力和平台成为开发新型突破性药物的领导者，以最大限度地提高治疗血液和实体恶性肿瘤的临床效益。有关更多信息，请访问www.eileanther.com。

Media Contact:Amy BurdCSO[email protected]

媒体联系人：Amy BurdCSO[受电子邮件保护]

SOURCE Eilean Therapeutics

来源Eilean Therapeutics